Download presentation
Presentation is loading. Please wait.
Published byRodrigo Toulson Modified over 9 years ago
1
ARRHYTHMIAS TACHYCARDIA>100/min BRADYCARDIA<50/min CARDIAC ARREST Electrical activity –ChaoticVF –Absentasystole
3
Action potential -60 0
4
Propagating action potential -60 0
5
Propagating action potential -60 0
6
Propagating action potential -60 0
7
Propagating action potential -60 0
8
Propagating action potential
9
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
10
DEPOL Inward REPOL outward
13
Propagating action potential
14
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
15
DEPOL Inward REPOL outward
17
DEPOL Inward REPOL outward
18
AUTOMATICITY Physiological: Sinus node Pathological: Reduction/depolarisation of resting membrane potential (e.g. Ischaemia)
19
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
20
Tachyarrhythmias Antiarrhythmic drugs –Vaughan-Williams Classification –Drugs divided according to EP effects on cells –All are negatively inotropic –Can also be pro-arrhythmic
21
Tachyarrhythmias Class I –Impede Na transport across cell membrane –Ia increase AP duration eg quinidine, disopyramide, procainamide –Ib shorten AP duration eg lignocaine, mexilitene, propafenone –Ic little effect on AP eg flecainide
22
Tachyarrhythmias Class II –Interfere with effects of SNS on the heart eg beta blockers Class III –Prolong AP duration but do not effect initial Na dependent phase eg sotalol, amiodarone Class IV –Antagonise Ca transport across cell membrane –SA and AV node particularly susceptible eg verapamil, diltiazem
25
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
26
AV Nodal block [Class II –Interfere with effects of SNS on the heart eg beta blockers] Class III –Prolong AP duration but do not effect initial Na dependent phase eg sotalol, amiodarone Class IV –Antagonise Ca transport across cell membrane –SA and AV node particularly susceptible eg verapamil, diltiazem Adenosine –Specific AV nodal block
29
EP study: standard fixed wires
34
RADIOFREQUENCY ABLATION
35
TREATMENT STRATEGY STABILISE AUTOMATICITY PROLONG ACTION POTENTIAL SLOW CONDUCTION INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
37
RFA: success rates AVJ98% AVNRT97% AP93% (L 95%, R 89%) AFl95% Infarct VT60-90%, long term 50% Idiopathic VT90% Focal AF60%
38
RFA: treatment of choice AVJ98% AVNRT97% AP93% (L 95%, R 89%) AFl95% Idiopathic VT90% ______________________________ ?Infarct VT60-90%, long term 50% ?Focal AF60%
41
Atrial flutter
42
Atrial Flutter: RFA vs AA drugs JACC2000;35:1898 prospective, randomised – 61 pts SR at 21 months:36%AAD vs 80% RFA Rehospitalised:63% AAD vs 22% RFA AF:53% AAD vs 29% RFA QOL:no change AAD improvement RFA
45
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
46
Concepts of AF: 1900-2000 MULTIPLE WAVELETS Ines, Garrey MOTHER WAVE Lewis HYPEREXCITABILITY Engelmann, Winterberg
49
WPW syndrome
51
AV re-entry tachycardia
57
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
59
Ventricular tachycardia
61
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
65
Rhythm Strip During Episode of Sudden Death
66
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
67
Implanatable defibrillators
68
Implanatable defibrillator in-situ
72
Sinus node disease
73
AV node disease 1st degree heart block 2nd degree heart block (2:1)
74
AV node disease Complete (3rd degree) heart block
75
Bradyarrhythmias AV node disease –1st degree; prolonged PR interval –2nd degree; Mobitz type I (Wenckebach); increasing PR interval then non-conducted P wave –2nd degree; Mobitz type II; non-conducted P waves –2nd degree; 2:1 or 3:1 AV node block –3rd degree; complete heart block AV block usually caused by idiopathic fibrosis; other causes include MI, drugs and congenital block
76
TREATMENT STRATEGY PROLONG ACTION POTENTIAL MODIFY CONDUCTION STABILISE AUTOMATICITY INTERRUPT REENTRY –PHARMACOLOGICAL –PHYSICAL ELECTRICAL STIMULATION –ATP/SHOCK TACHY –PACE BRADY
77
Bradyarrhythmias Treatment of symptomatic bradyarrhythmias often consists of pacing In the short-term drugs may be used to augment conduction eg atropine, isoprenaline
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.